drugset / Trial / NCT00433160

Phase 3 Clinical Trial of Teriparatide in Japan

NCT00433160

Phase 3 Completed 207 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of teriparatide based on measurements of bone mineral density at lumbar spine

Timeline

Start
2007-01
Primary completion
2008-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous

Indications